Sg3 Management, LLC Biomarin Pharmaceutical Inc Transaction History

Sg3 Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$80.93 - $108.63 $202,325 - $271,575	2,500 New	2,500 $258,000
Q2 2022 Aug 15, 2022	SELL	$71.48 - $86.85 $121,516 - $147,645	-1,700 Reduced 14.17%	10,300 $854,000
Q1 2022 May 16, 2022	SELL	$74.28 - $92.69 $1.52 Million - $1.9 Million	-20,500 Reduced 63.08%	12,000 $925,000
Q4 2021 Feb 15, 2022	BUY	$71.72 - $91.47 $537,900 - $686,025	7,500 Added 30.0%	32,500 $2.87 Million
Q3 2021 Nov 15, 2021	BUY	$74.77 - $85.47 $1.08 Million - $1.24 Million	14,500 Added 138.1%	25,000 $1.93 Million
Q2 2021 Aug 16, 2021	SELL	$75.51 - $84.79 $611,631 - $686,799	-8,100 Reduced 43.55%	10,500 $876,000
Q1 2021 May 17, 2021	SELL	$74.73 - $90.69 $1.3 Million - $1.57 Million	-17,365 Reduced 48.28%	18,600 $1.4 Million
Q4 2020 Feb 16, 2021	BUY	$72.61 - $90.2 $2.61 Million - $3.24 Million	35,965 New	35,965 $3.15 Million

635

178M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11.8B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.